In patients undergoing PCI, ticagrelor but not clopidogrel monotherapy was non-inferior to DAPT for the prevention of ischemic events and superior for net adverse clinical events. Major bleeding was similarly reduced with ticagrelor and clopidogrel. ja.ma/3x61HVV

Presented today at #ACC24: In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

ULTIMATE-DAPT results presented at #ACC24

Presented at #ACC24: FULL REVASC: In a registry-based trial, FFR-guided PCI of nonculprit lesions did not result in a lower risk of a composite of death from any cause, myocardial infarction, or unplanned revascularization than culprit-lesion-only PCI. nej.md/3xj5b7u

Secondary prevention of patients with chronic coronary syndrome is based on the long-term use of a single anti-platelet drug: which drug is considered more suitable remains matter of debate #Clopidogrel #Aspirin #CardioTwitter #CCS #Cardiology academic.oup.com/eurheartjsupp/…

#Controversy in cardiology: Clopidogrel or aspirin for the treatment of patients with CAD? 💊 Excellent review article by #LauraGatto, Lorenzo Scalia & colleagues 👉 ✅ Online: lnkd.in/dFFeY6U9 #PANTHER #DAPT #PCI #P2Y12 #ASA #CardioTwitter #CardioEd #Cardiology

📊🩸ARC-HBR criteria better discern clinical features of high bleeding risk patients. Our #POEM trial sub-analysis, online on #CRM, aimed to investigate cardiovascular outcomes when applying such criteria in HBR patients after PCI with #Synergy stent sciencedirect.com/science/articl…

The identification and management of patients at high bleeding risk (HBR) undergoing TAVI are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making. The Valve Academic Research Consortium

#EuroPCR 2024 Major LBTs: NOTION-2 This study provides further data concerning the 1-year outcome of younger AS patients with tricuspid valve anatomy treated with #TAVI compared to SAVR. In this population, TAVI and SAVR showed similar rates of the primary endpoint at 1 year,

#EuroPCR 2024 Major LBT – LANDMARK Previous head-to-head comparisons of new THVs with established devices confirmed no class effect of clinical benefits after #TAVI with inferior safety & efficacy for some of them. Validation of MyVal non-inferiority to the most widely used

#EuroPCR 2024 Major LBTs: REC-CAGEFREE II The results of this pioneering study, presented by Ling Tao. provides the 1st randomised data concerning the use of antiplatelet therapy in ACS patients treated with DCB. #interventionalcardiology

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.

This is a study inspired from and dedicated to Sanjay Kaul, where we investigated the effect of using absolute rather than relative noninferiority margins in cardiovascular randomized trials. Recalculating noninferiority margins based on actual event rates, rather than expected

How to retrieve your Prostyle when it gets stuck In challenging anatomies, the Prostyle may get stuck due to calcification, leading to urgent vascular surgery and increasing the operative risk for the patients. This #MyToolKit 🧰⚙️🪛 tutorial shows a step-by-step bailout

New 2024 #ESCGuidelines on #Afib 🆕! Use the CHA2DS2-VA score (without Sc) #ESCCongress European Society of Cardiology

How many times have we seen this flow chart on the duration of DAPT change over the years? Let’s summarize the situation regarding class I recommendations (“must be done”) as reported in the new 2024 guidelines on chronic coronary syndromes: - High bleeding risk patient: DAPT

The OCEANIC-AF trial, comparing asundexian to apixaban in patients with atrial fibrillation was halted early due to a significantly higher incidence of stroke or systemic embolism in the asundexian group. The findings raise questions about the adequacy of factor XIa inhibition

Live from the #ESCCongress 2024 in London 🇬🇧 NOTION 3 📊: PCI with #TAVI reduced death, MI, or urgent revascularization compared to TAVI alone but increased minor bleeding. However, the decision to proceed with PCI should be individualized according to patient characteristics.

This comprehensive review embraces the latest evidences of coronary revascularization management in transcatheter aortic valve implantation candidates; now available online on #ExpertReviewofMedicalDevices tandfonline.com/doi/full/10.10… #CAD #TAVI #CoronaryArteryDisease #CardioTwitter

[IT] Asundexian per la Fibrillazione Atriale: presentati all’ESC2024 i risultati dello studio OCEANIC-AF interrotto precocemente per endpoint ischemici elevati in confronto ad Apixaban. È ancora troppo presto per l’era degli antagonisti del fattore XIa? centrolottainfarto.com/allnews/antago…